Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11905455 | 0.89 | PDGFRB (0.65) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL10003275 | 0.87 | FLT3 (0.43) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL24019644 | 0.83 | FLT3 (0.63) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL10003921 | 0.81 | RXFP1 (0.50) | PDGFRBPDGFRAKMT2AMEN1RXFP1 | |
| SCHEMBL10002831 | 0.80 | FLT3 (0.60) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL10003620 | 0.78 | MMP9 (0.41) | — | |
| SCHEMBL30189510 | 0.78 | FLT3 (0.68) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL24113306 | 0.78 | FLT3 (0.68) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL335655 | 0.78 | FLT3 (0.68) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL10002715 | 0.77 | IDO1 (0.57) | FLT3KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471786-B1 | AMINOPYRAZOLE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2471786-A1 | AMINOPYRAZOLE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | FLT3 46/4885PDGFRB 36/4885PDGFRA 38/4885 |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 | FLT3 364/4885PDGFRB 3639/4885PDGFRA 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.